Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck Medicine, University of Southern California, discusses EGFR mutations in patients with lung cancer.
Gitlitz's case study highlights the exon 20 insertion, which is the third most common EGFR mutation. The first most common mutation is exon 19, and the second is the exon 20 mutation. Patients present with this exon 20 insertion, and they are resistant to the common EGFR tyrosine kinase inhibitor (TKI).
She stresses the importance of looking at the resistant mutation because while it still drives the cancer, the first and second generation EGFR inhibitors are not strong enough to inhibit the target.
Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck Medicine, University of Southern California, discusses EGFR mutations in patients with lung cancer.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More